Hansoh Pharma Licenses Hengrui’s Late-Stage Kidney Drug SHR6508 for China

The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).

Hansoh Pharmaceutical Group has signed a license agreement with Jiangsu Hengrui Pharmaceuticals to obtain exclusive rights to develop, manufacture and commercialise SHR6508 in mainland China, excluding Hong Kong, Macau and Taiwan. SHR6508, an allosteric modulator of the calcium-sensing receptor currently in Phase III clinical trials for secondary hyperparathyroidism in adult chronic kidney disease patients requiring hemodialysis, will require an upfront payment of RMB30 million, up to RMB190 million in potential milestone payments and tiered single-digit royalties on future net sales. The product is expected to complement Hansoh’s existing nephrology and dialysis portfolio, allowing the company to capitalise on its established commercial network to enhance execution efficiency and portfolio performance, while the relatively small transaction size means no notifiable or connected transaction implications under Hong Kong listing rules for shareholders.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$48.20 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a China-based pharmaceutical company focused on research, development, manufacturing and commercialization of innovative drugs, with established strengths in nephrology and dialysis-related therapies. The group leverages a nationwide commercialization infrastructure and market access capabilities to expand its portfolio across key therapeutic areas in the Chinese healthcare market.

Average Trading Volume: 8,057,398

Technical Sentiment Signal: Buy

Current Market Cap: HK$226.6B

See more data about 3692 stock on TipRanks’ Stock Analysis page.